Nearly one-quarter of Medicare's top-prescribing physicians received consulting fees or other financial perks from manufacturers of the drugs they prescribed in 2013, renewing nagging questions about conflicts of interest in medical decisionmaking.
A federal appeals court ruled Friday that Actavis must continue to sell an Alzheimer's drug it wanted to pull off the market to limit competition from generics. It's a case with potential implications for pharmaceutical companies and patients nationwide, experts say.
House committee members Thursday voted unanimously to move the proposed 21st Century Cures Act toward consideration by the full body.
Insiders say lawmakers are no closer to finding common ground on key funding issues that have postponed discussion on the proposed 21st Century Cures Act.
Contrary to public perception and horrific cases that make headlines, serious mental problems are declining among the nation's youth, and there has been a big rise in how many are getting help, a new study finds.
Johnson & Johnson expects a lucrative return from its pharmaceutical business, with plans to seek approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales.
The Food and Drug Administration is seeking details from manufacturers of antimicrobials that are used in livestock. It's part of an effort to reduce development of antibiotic-resistant “superbugs” that make drugs used in both animals and humans no longer effective.
The Food and Drug Administration is moving to collect more information on antibiotics used in animals that become meat. It's an effort to stem antibiotic-resistant diseases.
Diagnostic errors may be an overlooked factor in the battle to drive down the unnecessary use of antibiotics. In nearly every case where an initial diagnosis was undetermined or wrong, according to a new study, patients were given antibiotics they didn't need.
Drugmaker Endo International is climbing toward the top of the steadily consolidating generic medicine business with a deal to buy Par Pharmaceutical Holdings for about $8.05 billion.
The number of stem-cell clinics across the U.S. has surged from a handful in 2010 to more than 170 today. Many of the clinics are linked in large, for-profit chains. It's quackery, critics say. But it's also a mushrooming business—and almost wholly unregulated.
The FDA is warning that a new class of Type 2 diabetes medications called sodium-glucose cotransporter-2 inhibitors may lead to a serious, potentially fatal condition in which the body overproduces a chemical called ketone and results in too much acid in the blood.